Sun Phar­ma screech­es to the pso­ri­a­sis fin­ish line with FDA OK of Ilumya. Too bad ri­vals J&J and oth­ers beat them to it

In the crowd­ed race to launch new ther­a­pies for pso­ri­a­sis, In­dia’s largest drug­mak­er Sun Phar­ma hus­tled to the fin­ish line Thurs­day with FDA ap­proval of tildrak­izum­ab. Un­for­tu­nate­ly for Sun, sev­er­al oth­er drug­mak­ers were al­ready there wait­ing.

The com­pa­ny’s bi­o­log­ic, which is now brand­ed as Ilumya, was first in-li­censed from Mer­ck back in 2014 for $80 mil­lion. The med, de­liv­ered through sub­cu­ta­neous in­jec­tion, was al­ready in Phase III tri­als at the time of the deal, and Mer­ck hand­ed all reg­u­la­to­ry and launch re­spon­si­bil­i­ties over to Sun.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.